TABLE 3.

Daily TKI dose at the time of the first QTcf prolongation and the duration from TKI initiation and the development of the first QTcf prolongation for the following TKIs: Imatinib, Dasatinib, Sunitinib, Pazopanib and Nilotinib

	Number ofTKI	Daily TKI dose at the time	Duration from TKI initiation and the first QTcf prolongation
Type ofTKI	administrations that cause QTcf prolongation	of the first QTcf prolongation	<1 month	1–3 months	3–6 months	6 months-1 year	>1 year
Imatinib	48	200 mg: 1 (2.1%) 300 mg: 2 (4.2%) 400 mg: 35 (72.9%) 500 mg: 1 (2.1%) 600 mg: 6 (12.5%) 800 mg: 3 (6.3%)	10 (20.8%)	16 (33.3%)	15 (31.3%)	3 (6.3%)	4 (8.3%)
Pazopanib	32	200 mg: 2 (6.3%) 400 mg: 7 (21.9%) 600 mg 10 (31.3%) 800 mg: 13 (40.6%)	6 (18.8%)	12 (37.5%)	10 (31.3%)	2 (6.3%)	2 (6.3%)
Sunitinib	26	25 mg: 3 (11.5%) 37.5 mg: 8 (30.8%) 50 mg: 15 (57.7%)	5 (19.2%)	9 (34.6%)	11 (42.3%)	0 (0%)	1 (3.9%)
Dasatinib	48	20 mg: 3 (6.3%) 50 mg: 6 (12.5%) 70 mg: 8 (16.7%) 100 mg: 20 (41.2%) 140 mg: 11 (22.9%)	10 (20.8%)	16 (33.3%)	17 (35.4%)	3 (6.3%)	2 (4.2%)
Nilotinib	29	300 mg: 2 (6.9%) 400 mg: 3 (10.3%) 600 mg: 5 (17.2%) 800 mg: 19 (65.5%)	7 (24.1%)	10 (34.5%)	7 (24.1%)	3 (10.3%)	2 (6.9%)
Total	183		38 (20.8%)	63 (34.4%)	60 (32.8%)	11(6.0%)	10 (5.5%)